Select Page

Study Evaluates Whether Neuropathic Pain, Depression Can Be Simultaneously Treated by Psilocybin

Media Partners, Psychedelic News Wire

This post is presented by our media partner Psychedelic News Wire
View the original article here.

Chronic pain is one of the most prolific causes of disability on the planet, forcing millions of people worldwide to deal with debilitating pain on a daily basis and costing the global economy billions of dollars. Although the condition occurs due to a variety of reasons, the similarity among all people with chronic and neuropathic pain is that it causes significant physical and mental suffering, as well as stress and insomnia that exacerbate the risk of developing depression.

The physical limitations neuropathic pain places on patients can also prevent people from taking part in day-to-day activities and favorite hobbies, reducing their quality of life and increasing their depression risk.

Researchers are now looking into the possibility of treating both neuropathic pain and depression with psilocybin, the main psychoactive agent in magic mushrooms. Prior studies have already shown that psychedelics such as psilocybin can deliver long-term relief against mental disorders, including depression and anxiety. Unfortunately, depression tends to be associated with chronic pain, which can be quite hard to treat and often leaves patients addicted to pharmaceutical opioids.

Ahmad Hammo, a third-year bioengineering student at the University of Pennsylvania School of Engineering and Applied Science, is running a pilot study exploring magic mushrooms’ potential as a treatment for both depression and chronic pain. Hammo explains that the “strong correlation” between the two conditions piqued his interest in whether psychedelics could potentially treat both chronic pain and depression simultaneously.

Current treatments for both depression and chronic pain aren’t effective for many patients and they are often associated with side effects. However, the recent surge in psychedelic research revealed that hallucinogenics such as psilocybin and LSD can alleviate the symptoms of both depression and chronic neuropathic pain.

However, the findings on chronic pain and depression come from studies that looked at the effect of psychedelics on one condition rather than both, and research specifically looking at psychedelics as potential treatments for chronic pain is sparse. Hammo’s study will be among the first to analyze the potential benefit of using psilocybin to treat depression and chronic pain simultaneously.

The Center for Undergraduate Research and Fellowship will support the research under its Penn Undergraduate Research Mentoring (PURM) program. Perelman School of Medicine assistant professor, neuroscientist and neuro anesthesiologist Joseph Cichon will guide Hammo over the course of the project. Although Cichon’s lab has previously been involved in studies investigating the effects of psychedelics such as ketamine on the brain, this will be the first time someone in Cichon’s group has elected to study’s psilocybin’s effect on chronic pain.

As more of these studies are conducted, startups such as Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) are likely to be validated in the direction they are taking to develop additional treatments from different psychedelics.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.

This post was originally published by our media partner here.